<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35306933</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening.</ArticleTitle>
        <Pagination>
          <StartPage>912</StartPage>
          <EndPage>929</EndPage>
          <MedlinePgn>912-929</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2045590</ELocationID>
        <Abstract>
          <AbstractText>Trypanothione synthetase (TryS) catalyses the synthesis of <i>N</i><sup>1</sup><i>,N<sup>8</sup></i>-bis(glutathionyl)spermidine (trypanothione), which is the main low molecular mass thiol supporting several redox functions in trypanosomatids. TryS attracts attention as molecular target for drug development against pathogens causing severe and fatal diseases in mammals. A drug discovery campaign aimed to identify and characterise new inhibitors of TryS with promising biological activity was conducted. A large compound library (<i>n</i> = 51,624), most of them bearing drug-like properties, was primarily screened against TryS from <i>Trypanosoma brucei</i> (<i>Tb</i>TryS). With a true-hit rate of 0.056%, several of the <i>Tb</i>TryS hits (IC<sub>50</sub> from 1.2 to 36 µM) also targeted the homologue enzyme from <i>Leishmania infantum</i> and <i>Trypanosoma cruzi</i> (IC<sub>50</sub> values from 2.6 to 40 µM). Calmidazolium chloride and Ebselen stand out for their multi-species anti-TryS activity at low µM concentrations (IC<sub>50</sub> from 2.6 to 13.8 µM). The moieties carboxy piperidine amide and amide methyl thiazole phenyl were identified as novel <i>Tb</i>TryS inhibitor scaffolds. Several of the TryS hits presented one-digit µM EC<sub>50</sub> against <i>T. cruzi</i> and <i>L. donovani</i> amastigotes but proved cytotoxic against the human osteosarcoma and macrophage host cells (selectivity index ≤ 3). In contrast, seven hits showed a significantly higher selectivity against <i>T. b. brucei</i> (selectivity index from 11 to 182). Non-invasive redox assays confirmed that Ebselen, a multi-TryS inhibitor, induces an intracellular oxidative milieu in bloodstream <i>T. b. brucei</i>. Kinetic and mass spectrometry analysis revealed that Ebselen is a slow-binding inhibitor that modifies irreversible a highly conserved cysteine residue from the TryS's synthetase domain. The most potent <i>Tb</i>TryS inhibitor (a singleton containing an adamantine moiety) exerted a non-covalent, non-competitive (with any of the substrates) inhibition of the enzyme. These data feed the drug discovery pipeline for trypanosomatids with novel and valuable information on chemical entities with drug potential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Benítez</LastName>
            <ForeName>Diego</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franco</LastName>
            <ForeName>Jaime</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sardi</LastName>
            <ForeName>Florencia</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leyva</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durán</LastName>
            <ForeName>Rosario</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Gahee</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Gyongseon</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Taehee</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Namyoul</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heo</LastName>
            <ForeName>Jinyeong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Kideok</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Honggun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Inhee</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radu</LastName>
            <ForeName>Constantin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shum</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>No</LastName>
            <ForeName>Joo Hwan</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Comini</LastName>
            <ForeName>Marcelo A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000981">Antiprotozoal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.1.-</RegistryNumber>
          <NameOfSubstance UI="D019732">Amide Synthases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.1.9</RegistryNumber>
          <NameOfSubstance UI="C064407">trypanothione synthetase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019732" MajorTopicYN="N">Amide Synthases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000981" MajorTopicYN="N">Antiprotozoal Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018314" MajorTopicYN="N">Leishmania infantum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014349" MajorTopicYN="N">Trypanosoma cruzi</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Leishmania</Keyword>
        <Keyword MajorTopicYN="N">Trypanosoma</Keyword>
        <Keyword MajorTopicYN="N">Trypanothione synthetase</Keyword>
        <Keyword MajorTopicYN="N">covalent inhibitor</Keyword>
        <Keyword MajorTopicYN="N">non-competitive inhibition</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35306933</ArticleId>
        <ArticleId IdType="pmc">PMC8942522</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2045590</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO.  Research priorities for Chagas disease, Human African Trypanosomiasis and Leishmaniasis. Technical report of the TDR disease reference group on Chagas disease, Human African Trypanosomiasis and Leishmaniasis. Technical Report 2012. https://apps.who.int/iris/handle/10665/77472</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23484340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comini MA, Flohé L.. 
The trypanothione-based redox metabolism of trypanosomatids. In: T Jäger, O Koch, L Flohé, eds. Trypanosomatids diseases: molecular routes to drug discovery (drug discovery in infectious diseases). Oxford: Wiley-Blackwell; 2013:167–199.</Citation>
        </Reference>
        <Reference>
          <Citation>Anantharaman V, Aravind L.. 
Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol
2003;4:R11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151301</ArticleId>
            <ArticleId IdType="pubmed">12620121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fawaz MV, Topper ME, Firestine SM.. 
The ATP-grasp enzymes. Bioorg Chem
2011;39:185–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243065</ArticleId>
            <ArticleId IdType="pubmed">21920581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comini MA, Biosynthesis of polyamine–glutathione derivatives in Enterobacteria and Kinetoplastida. In: Flohé L, ed. Glutathione. London: CRC Press; 2018:285–305.</Citation>
        </Reference>
        <Reference>
          <Citation>Comini MA, Guerrero SA, Haile S, et al. . 
Validation of Trypanosoma brucei trypanothione synthetase as drug target. Free Radic Biol Med
2004;36:1289–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15110394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ariyanayagam MR, Oza SL, Guther ML, Fairlamb AH.. 
Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochem J
2005;391:425–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1276942</ArticleId>
            <ArticleId IdType="pubmed">16008527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sousa AF, Gomes-Alves AG, Benítez D, et al. . 
Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum. Free Radic Biol Med
2014;73:229–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24853758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesías AC, Sasoni N, Arias DG, et al. . 
Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi. Free Radic Biol Med
2019;130:23–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6331241</ArticleId>
            <ArticleId IdType="pubmed">30359758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manta B, Bonilla M, Fiestas L, et al. . 
Polyamine-based thiols in trypanosomatids: evolution, protein structural adaptations, and biological functions. Antioxid Redox Signal
2018;28:463–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29048199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyllie S, Oza SL, Patterson S, et al. . 
Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Mol Microbiol
2009;74:529–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2784880</ArticleId>
            <ArticleId IdType="pubmed">19558432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrie LS, Wyllie S, Spinks D, et al. . 
Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. J Biol Chem
2009;284:36137–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2794729</ArticleId>
            <ArticleId IdType="pubmed">19828449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros A, Benítez D, Korn RS, et al. . 
Mechanistic and biological characterisation of novel N5-substituted paullones targeting the biosynthesis of trypanothione in Leishmania. J Enzyme Inhib Med Chem
2020;35:1345–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7717452</ArticleId>
            <ArticleId IdType="pubmed">32588679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olin-Sandoval V, González-Chávez Z, Berzunza-Cruz M, et al. . 
Drug target validation of the trypanothione pathway enzymes through metabolic modelling. Febs J
2012;279:1811–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22394478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Lin CH, Walsh CT, Coward JK.. 
Novel inhibitors of trypanothione biosynthesis: synthesis and evaluation of a phosphinate analog of glutathionyl spermidine (GSP), a potent, slow binding inhibitor of GSP synthetase. Bioorg Med Chem Lett
1997;7:505–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen S, Lin CH, Kwon DS, et al. . 
Design, synthesis, and biochemical evaluation of phosphonate and phosphonamidate analogs of glutathionylspermidine as inhibitors of glutathionylspermidine synthetase/amidase from Escherichia coli. J Med Chem
1997;40:3842–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9371250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verbruggen C, De Craecker S, Rajan PK, et al. . 
Phosphonic acid and phosphinic acid tripeptides as inhibitors of glutathionylspermidine synthetase. Bioorg Med Chem Lett
1996;6:253–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwon DS, Lin CH, Chen S, et al. . 
Dissection of glutathionylspermidine synthetase/amidase from Escherichia coli into autonomously folding and functional synthetase and amidase domains. J Biol Chem
1997;272:2429–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8999955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CH, Chen S, Kwon DS, et al. . 
Aldehyde and phosphinate analogs of glutathione and glutathionylspermidine: potent, selective binding inhibitors of the E. coli bifunctional glutathionylspermidine synthetase/amidase. Chem Biol
1997;4:859–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9384533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amssoms K, Oza SL, Ravaschino E, et al. . 
Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: substitution of the glycine carboxylic acid group. Bioorg Med Chem Lett
2002;12:2553–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12182858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amssoms K, Oza SL, Augustyns K, et al. . 
Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: substitution of the glycine part. Bioorg Med Chem Lett
2002;12:2703–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12217358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza SL, Chen S, Wyllie S, et al. . 
ATP-dependent ligases in trypanothione biosynthesis-kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. Febs J
2008;275:5408–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2702004</ArticleId>
            <ArticleId IdType="pubmed">18959765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Silva C, Daunes S.. 
Structure-activity study on the in vitro antiprotozoal activity of glutathione derivatives. J Med Chem
2000;43:2072–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10821719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spinks D, Torrie LS, Thompson S, et al. . 
Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem
2012;7:95–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3320663</ArticleId>
            <ArticleId IdType="pubmed">22162199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benítez D, Medeiros A, Fiestas L, et al. . 
Identification of novel chemical scaffolds inhibiting trypanothione synthetase from pathogenic trypanosomatids. PLoS Negl Trop Dis
2016;10:e0004617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4829233</ArticleId>
            <ArticleId IdType="pubmed">27070550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orban OC, Korn RS, Benítez D, et al. . 
5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms. Bioorg Med Chem
2016;24:3790–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27349574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biebinger S, Wirtz LE, Lorenz P, Clayton C.. 
Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei. Mol Biochem Parasitol
1997;85:99–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9108552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutscher M, Pauleau AL, Marty L, et al. . 
Real-time imaging of the intracellular glutathione redox potential. Nat Methods
2008;5:553–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18469822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirumi H, Hirumi K.. 
Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol
1989;75:985–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2614608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiwald F, Benítez D, Charquero D, et al. . 
9- and 11-Substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. Eur J Med Chem
2014;83:274–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24973661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho PC, Lima DB, Leprevost FV, et al. . 
Integrated analysis of shotgun proteomic data with PatternLab for proteomics 4.0. Nat Protoc
2016;11:102–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5722229</ArticleId>
            <ArticleId IdType="pubmed">26658470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Riverol Y, Csordas A, Bai J, et al. . 
The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res
2019;47:D442–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323896</ArticleId>
            <ArticleId IdType="pubmed">30395289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza SL, Ariyanayagam MR, Aitcheson N, Fairlamb AH.. 
Properties of trypanothione synthetase from Trypanosoma brucei. Mol Biochem Parasitol
2003;131:25–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12967709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JH, Chung TD, Oldenburg KR.. 
A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen
1999;4:67–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10838414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Don R, Ioset JR.. 
Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology
2014;141:140–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23985066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebersoll S, Bogacz M, Günter LM, et al. . 
A tryparedoxin-coupled biosensor reveals a mitochondrial trypanothione metabolism in trypanosomes. Elife
2020;9:e53227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7046469</ArticleId>
            <ArticleId IdType="pubmed">32003744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Sardi F, Szilágyi L, et al. . 
Diglycosyl diselenides alter redox homeostasis and glucose consumption of infective African trypanosomes. Int J Parasitol Drugs Drug Resist
2017;7:303–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5565762</ArticleId>
            <ArticleId IdType="pubmed">28826037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Medeiros A, Benítez D, et al. . 
In vitro activity and mode of action of distamycin analogues against African trypanosomes. Eur J Med Chem
2017;126:776–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27951486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez Arce E, Putzu E, Lapier M, et al. . 
New heterobimetallic ferrocenyl derivatives are promising antitrypanosomal agents. Dalton Trans
2019;48:7644–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31049548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Scarone L, Comini MA.. 
Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency. Eur J Med Chem
2020;189:112043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31978782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivas F, Medeiros A, Quiroga C, et al. . 
New Pd-Fe ferrocenyl antiparasitic compounds with bioactive 8-hydroxyquinoline ligands: a comparative study with their Pt-Fe analogues. Dalton Trans
2021;50:1651–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33449983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortíz C, Moraca F, Laverriere M, et al. . 
Glucose 6-phosphate dehydrogenase from trypanosomes: selectivity for steroids and chemical validation in bloodstream Trypanosoma brucei. Molecules
2021;26:358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7826790</ArticleId>
            <ArticleId IdType="pubmed">33445584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Scarone L, Comini MA, Drugs and drug resistance in African and American Trypanosomiasis. In: Botta M, ed. Annual reports in medicinal chemistry: neglected diseases: extensive space for modern drug discovery. New York (NY): Academic Press, Elsevier Inc.; 2018:97–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Talevi A, Carrillo C, Comini M.. 
The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies. Curr Med Chem
2019;26:6614–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30259812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccoliti F, Di Santo R, Costi R.. 
Recent advancement in the search of innovative antiprotozoal agents targeting trypanothione metabolism. ChemMedChem
2020;15:2420–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32805075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fyfe PK, Oza SL, Fairlamb AH, Hunter WN.. 
Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities. J Biol Chem
2008;283:17672–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2427367</ArticleId>
            <ArticleId IdType="pubmed">18420578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch O, Cappel D, Nocker M, et al. . 
Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS One
2013;8:e56788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3581523</ArticleId>
            <ArticleId IdType="pubmed">23451087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leroux AE, Haanstra JR, Bakker BM, Krauth-Siegel RL.. 
Dissecting the catalytic mechanism of Trypanosoma brucei trypanothione synthetase by kinetic analysis and computational modeling. J Biol Chem
2013;288:23751–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3745322</ArticleId>
            <ArticleId IdType="pubmed">23814051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duty S, Jenner P.. 
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol
2011;164:1357–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3229766</ArticleId>
            <ArticleId IdType="pubmed">21486284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simeonov A, Kulkarni A, Dorjsuren D, et al. . 
Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One
2009;4:e57403rd.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2685009</ArticleId>
            <ArticleId IdType="pubmed">19484131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandramouly G, McDevitt S, Sullivan K, et al. . 
Small-molecule disruption of RAD52 rings as a mechanism for precision medicine in BRCA-deficient cancers. Chem Biol
2015;22:1491–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701204</ArticleId>
            <ArticleId IdType="pubmed">26548611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devkota AK, Tavares CD, Warthaka M, et al. . 
Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact. Biochemistry
2012;51:2100–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3673019</ArticleId>
            <ArticleId IdType="pubmed">22352903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W, Fricke N, Conery AL, et al. . 
NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption. Future Med Chem
2016;8:257–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4976882</ArticleId>
            <ArticleId IdType="pubmed">26910612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachojannis C, Magora F, Chrubasik S.. 
Rise and fall of oral health products with Canadian bloodroot extract. Phytother Res
2012;26:1423–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22318955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debiton E, Madelmont JC, Legault J, Barthomeuf C.. 
Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion. Cancer Chemother Pharmacol
2003;51:474–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12700925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson KW, Coll RJ, Murphy AJ.. 
Inhibition of skeletal muscle sarcoplasmic reticulum CaATPase activity by calmidazolium. J Biol Chem
1984;259:11487–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6236226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gietzen K.
Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem J
1983;216:611–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1152553</ArticleId>
            <ArticleId IdType="pubmed">6141789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Marchan Y, Sojo F, Rodriguez E, et al. . 
Trypanosoma cruzi calmodulin: cloning, expression and characterization. Exp Parasitol
2009;123:326–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19703447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terentis AC, Freewan M, Sempértegui Plaza TS, et al. . 
The selenazal drug Ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues. Biochemistry
2010;49:591–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20000778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J, Vodnala SK, Gustavsson AL, et al. . 
Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei. J Biol Chem
2013;288:27456–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3779740</ArticleId>
            <ArticleId IdType="pubmed">23900839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joice AC, Harris MT, Kahney EW, et al. . 
Exploring the mode of action of Ebselen in Trypanosoma brucei hexokinase inhibition. Int J Parasitol Drugs Drug Resist
2013;3:154–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3862409</ArticleId>
            <ArticleId IdType="pubmed">24533305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharlow ER, Lyda TA, Dodson HC, et al. . 
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis
2010;4:e659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2854128</ArticleId>
            <ArticleId IdType="pubmed">20405000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi T, Sano K, Takakura K, et al. . 
Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen study group. Stroke
1998;29:12–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9445321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Cooper CM, et al. . 
Effects of the potential lithium-mimetic, Ebselen, on impulsivity and emotional processing. Psychopharmacology (Berl)
2016;233:2655–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4917572</ArticleId>
            <ArticleId IdType="pubmed">27256357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Sharpley AL, Emir UE, et al. . 
Effect of the putative lithium mimetic Ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology
2016;41:1768–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4770517</ArticleId>
            <ArticleId IdType="pubmed">26593266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kil J, Lobarinas E, Spankovich C, et al. . 
Safety and efficacy of Ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet
2017;390:969–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28716314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young J, Kima PE.. 
The Leishmania parasitophorous vacuole membrane at the parasite–host interface. Yale J Biol Med
2019;92:511–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6747952</ArticleId>
            <ArticleId IdType="pubmed">31543712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoine JC, Prina E, Jouanne C, Bongrand P.. 
Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun
1990;58:779–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC258533</ArticleId>
            <ArticleId IdType="pubmed">1689700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alice JI, Bellera CL, Benítez D, et al. . 
Ensemble learning application to discover new trypanothione synthetase inhibitors. Mol Divers
2021;25:1361–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34264440</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35306933</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Drug-like molecules with anti-trypanothione synthetase activity identified by high throughput screening.</ArticleTitle>
        <Pagination>
          <StartPage>912</StartPage>
          <EndPage>929</EndPage>
          <MedlinePgn>912-929</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2045590</ELocationID>
        <Abstract>
          <AbstractText>Trypanothione synthetase (TryS) catalyses the synthesis of <i>N</i><sup>1</sup><i>,N<sup>8</sup></i>-bis(glutathionyl)spermidine (trypanothione), which is the main low molecular mass thiol supporting several redox functions in trypanosomatids. TryS attracts attention as molecular target for drug development against pathogens causing severe and fatal diseases in mammals. A drug discovery campaign aimed to identify and characterise new inhibitors of TryS with promising biological activity was conducted. A large compound library (<i>n</i> = 51,624), most of them bearing drug-like properties, was primarily screened against TryS from <i>Trypanosoma brucei</i> (<i>Tb</i>TryS). With a true-hit rate of 0.056%, several of the <i>Tb</i>TryS hits (IC<sub>50</sub> from 1.2 to 36 µM) also targeted the homologue enzyme from <i>Leishmania infantum</i> and <i>Trypanosoma cruzi</i> (IC<sub>50</sub> values from 2.6 to 40 µM). Calmidazolium chloride and Ebselen stand out for their multi-species anti-TryS activity at low µM concentrations (IC<sub>50</sub> from 2.6 to 13.8 µM). The moieties carboxy piperidine amide and amide methyl thiazole phenyl were identified as novel <i>Tb</i>TryS inhibitor scaffolds. Several of the TryS hits presented one-digit µM EC<sub>50</sub> against <i>T. cruzi</i> and <i>L. donovani</i> amastigotes but proved cytotoxic against the human osteosarcoma and macrophage host cells (selectivity index ≤ 3). In contrast, seven hits showed a significantly higher selectivity against <i>T. b. brucei</i> (selectivity index from 11 to 182). Non-invasive redox assays confirmed that Ebselen, a multi-TryS inhibitor, induces an intracellular oxidative milieu in bloodstream <i>T. b. brucei</i>. Kinetic and mass spectrometry analysis revealed that Ebselen is a slow-binding inhibitor that modifies irreversible a highly conserved cysteine residue from the TryS's synthetase domain. The most potent <i>Tb</i>TryS inhibitor (a singleton containing an adamantine moiety) exerted a non-covalent, non-competitive (with any of the substrates) inhibition of the enzyme. These data feed the drug discovery pipeline for trypanosomatids with novel and valuable information on chemical entities with drug potential.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Benítez</LastName>
            <ForeName>Diego</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Franco</LastName>
            <ForeName>Jaime</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sardi</LastName>
            <ForeName>Florencia</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leyva</LastName>
            <ForeName>Alejandro</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Durán</LastName>
            <ForeName>Rosario</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Analytical Biochemistry and Proteomics Unit, Institut Pasteur de Montevideo, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Gahee</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Gyongseon</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Taehee</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Namyoul</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Heo</LastName>
            <ForeName>Jinyeong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Kideok</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Honggun</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Inhee</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Medicinal Chemistry, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Radu</LastName>
            <ForeName>Constantin</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Automation and Logistics Management, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shum</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Assay Development and Screening, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>No</LastName>
            <ForeName>Joo Hwan</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>Host-Parasite Research Laboratory, Institut Pasteur Korea, Gyeonggi-do, Republic of Korea.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Comini</LastName>
            <ForeName>Marcelo A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory Redox Biology of Trypanosomes, Institut Pasteur de Montevideo, Montevideo, Uruguay.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000981">Antiprotozoal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.1.-</RegistryNumber>
          <NameOfSubstance UI="D019732">Amide Synthases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 6.3.1.9</RegistryNumber>
          <NameOfSubstance UI="C064407">trypanothione synthetase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019732" MajorTopicYN="N">Amide Synthases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000981" MajorTopicYN="N">Antiprotozoal Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018314" MajorTopicYN="N">Leishmania infantum</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014349" MajorTopicYN="N">Trypanosoma cruzi</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Leishmania</Keyword>
        <Keyword MajorTopicYN="N">Trypanosoma</Keyword>
        <Keyword MajorTopicYN="N">Trypanothione synthetase</Keyword>
        <Keyword MajorTopicYN="N">covalent inhibitor</Keyword>
        <Keyword MajorTopicYN="N">non-competitive inhibition</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35306933</ArticleId>
        <ArticleId IdType="pmc">PMC8942522</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2045590</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>WHO.  Research priorities for Chagas disease, Human African Trypanosomiasis and Leishmaniasis. Technical report of the TDR disease reference group on Chagas disease, Human African Trypanosomiasis and Leishmaniasis. Technical Report 2012. https://apps.who.int/iris/handle/10665/77472</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23484340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comini MA, Flohé L.. 
The trypanothione-based redox metabolism of trypanosomatids. In: T Jäger, O Koch, L Flohé, eds. Trypanosomatids diseases: molecular routes to drug discovery (drug discovery in infectious diseases). Oxford: Wiley-Blackwell; 2013:167–199.</Citation>
        </Reference>
        <Reference>
          <Citation>Anantharaman V, Aravind L.. 
Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol
2003;4:R11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151301</ArticleId>
            <ArticleId IdType="pubmed">12620121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fawaz MV, Topper ME, Firestine SM.. 
The ATP-grasp enzymes. Bioorg Chem
2011;39:185–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3243065</ArticleId>
            <ArticleId IdType="pubmed">21920581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Comini MA, Biosynthesis of polyamine–glutathione derivatives in Enterobacteria and Kinetoplastida. In: Flohé L, ed. Glutathione. London: CRC Press; 2018:285–305.</Citation>
        </Reference>
        <Reference>
          <Citation>Comini MA, Guerrero SA, Haile S, et al. . 
Validation of Trypanosoma brucei trypanothione synthetase as drug target. Free Radic Biol Med
2004;36:1289–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15110394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ariyanayagam MR, Oza SL, Guther ML, Fairlamb AH.. 
Phenotypic analysis of trypanothione synthetase knockdown in the African trypanosome. Biochem J
2005;391:425–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1276942</ArticleId>
            <ArticleId IdType="pubmed">16008527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sousa AF, Gomes-Alves AG, Benítez D, et al. . 
Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum. Free Radic Biol Med
2014;73:229–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24853758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mesías AC, Sasoni N, Arias DG, et al. . 
Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi. Free Radic Biol Med
2019;130:23–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6331241</ArticleId>
            <ArticleId IdType="pubmed">30359758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manta B, Bonilla M, Fiestas L, et al. . 
Polyamine-based thiols in trypanosomatids: evolution, protein structural adaptations, and biological functions. Antioxid Redox Signal
2018;28:463–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29048199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyllie S, Oza SL, Patterson S, et al. . 
Dissecting the essentiality of the bifunctional trypanothione synthetase-amidase in Trypanosoma brucei using chemical and genetic methods. Mol Microbiol
2009;74:529–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2784880</ArticleId>
            <ArticleId IdType="pubmed">19558432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrie LS, Wyllie S, Spinks D, et al. . 
Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. J Biol Chem
2009;284:36137–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2794729</ArticleId>
            <ArticleId IdType="pubmed">19828449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros A, Benítez D, Korn RS, et al. . 
Mechanistic and biological characterisation of novel N5-substituted paullones targeting the biosynthesis of trypanothione in Leishmania. J Enzyme Inhib Med Chem
2020;35:1345–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7717452</ArticleId>
            <ArticleId IdType="pubmed">32588679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olin-Sandoval V, González-Chávez Z, Berzunza-Cruz M, et al. . 
Drug target validation of the trypanothione pathway enzymes through metabolic modelling. Febs J
2012;279:1811–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22394478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Lin CH, Walsh CT, Coward JK.. 
Novel inhibitors of trypanothione biosynthesis: synthesis and evaluation of a phosphinate analog of glutathionyl spermidine (GSP), a potent, slow binding inhibitor of GSP synthetase. Bioorg Med Chem Lett
1997;7:505–10.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen S, Lin CH, Kwon DS, et al. . 
Design, synthesis, and biochemical evaluation of phosphonate and phosphonamidate analogs of glutathionylspermidine as inhibitors of glutathionylspermidine synthetase/amidase from Escherichia coli. J Med Chem
1997;40:3842–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9371250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verbruggen C, De Craecker S, Rajan PK, et al. . 
Phosphonic acid and phosphinic acid tripeptides as inhibitors of glutathionylspermidine synthetase. Bioorg Med Chem Lett
1996;6:253–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwon DS, Lin CH, Chen S, et al. . 
Dissection of glutathionylspermidine synthetase/amidase from Escherichia coli into autonomously folding and functional synthetase and amidase domains. J Biol Chem
1997;272:2429–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8999955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin CH, Chen S, Kwon DS, et al. . 
Aldehyde and phosphinate analogs of glutathione and glutathionylspermidine: potent, selective binding inhibitors of the E. coli bifunctional glutathionylspermidine synthetase/amidase. Chem Biol
1997;4:859–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9384533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amssoms K, Oza SL, Ravaschino E, et al. . 
Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 1: substitution of the glycine carboxylic acid group. Bioorg Med Chem Lett
2002;12:2553–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12182858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amssoms K, Oza SL, Augustyns K, et al. . 
Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: substitution of the glycine part. Bioorg Med Chem Lett
2002;12:2703–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12217358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza SL, Chen S, Wyllie S, et al. . 
ATP-dependent ligases in trypanothione biosynthesis-kinetics of catalysis and inhibition by phosphinic acid pseudopeptides. Febs J
2008;275:5408–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2702004</ArticleId>
            <ArticleId IdType="pubmed">18959765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Silva C, Daunes S.. 
Structure-activity study on the in vitro antiprotozoal activity of glutathione derivatives. J Med Chem
2000;43:2072–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10821719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spinks D, Torrie LS, Thompson S, et al. . 
Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem
2012;7:95–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3320663</ArticleId>
            <ArticleId IdType="pubmed">22162199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benítez D, Medeiros A, Fiestas L, et al. . 
Identification of novel chemical scaffolds inhibiting trypanothione synthetase from pathogenic trypanosomatids. PLoS Negl Trop Dis
2016;10:e0004617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4829233</ArticleId>
            <ArticleId IdType="pubmed">27070550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orban OC, Korn RS, Benítez D, et al. . 
5-Substituted 3-chlorokenpaullone derivatives are potent inhibitors of Trypanosoma brucei bloodstream forms. Bioorg Med Chem
2016;24:3790–800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27349574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biebinger S, Wirtz LE, Lorenz P, Clayton C.. 
Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei. Mol Biochem Parasitol
1997;85:99–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9108552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutscher M, Pauleau AL, Marty L, et al. . 
Real-time imaging of the intracellular glutathione redox potential. Nat Methods
2008;5:553–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18469822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirumi H, Hirumi K.. 
Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J Parasitol
1989;75:985–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2614608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiwald F, Benítez D, Charquero D, et al. . 
9- and 11-Substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. Eur J Med Chem
2014;83:274–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24973661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho PC, Lima DB, Leprevost FV, et al. . 
Integrated analysis of shotgun proteomic data with PatternLab for proteomics 4.0. Nat Protoc
2016;11:102–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5722229</ArticleId>
            <ArticleId IdType="pubmed">26658470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez-Riverol Y, Csordas A, Bai J, et al. . 
The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res
2019;47:D442–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6323896</ArticleId>
            <ArticleId IdType="pubmed">30395289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza SL, Ariyanayagam MR, Aitcheson N, Fairlamb AH.. 
Properties of trypanothione synthetase from Trypanosoma brucei. Mol Biochem Parasitol
2003;131:25–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12967709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JH, Chung TD, Oldenburg KR.. 
A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen
1999;4:67–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10838414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Don R, Ioset JR.. 
Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology
2014;141:140–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23985066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebersoll S, Bogacz M, Günter LM, et al. . 
A tryparedoxin-coupled biosensor reveals a mitochondrial trypanothione metabolism in trypanosomes. Elife
2020;9:e53227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7046469</ArticleId>
            <ArticleId IdType="pubmed">32003744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Sardi F, Szilágyi L, et al. . 
Diglycosyl diselenides alter redox homeostasis and glucose consumption of infective African trypanosomes. Int J Parasitol Drugs Drug Resist
2017;7:303–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5565762</ArticleId>
            <ArticleId IdType="pubmed">28826037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Medeiros A, Benítez D, et al. . 
In vitro activity and mode of action of distamycin analogues against African trypanosomes. Eur J Med Chem
2017;126:776–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27951486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez Arce E, Putzu E, Lapier M, et al. . 
New heterobimetallic ferrocenyl derivatives are promising antitrypanosomal agents. Dalton Trans
2019;48:7644–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31049548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Scarone L, Comini MA.. 
Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency. Eur J Med Chem
2020;189:112043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31978782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rivas F, Medeiros A, Quiroga C, et al. . 
New Pd-Fe ferrocenyl antiparasitic compounds with bioactive 8-hydroxyquinoline ligands: a comparative study with their Pt-Fe analogues. Dalton Trans
2021;50:1651–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33449983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortíz C, Moraca F, Laverriere M, et al. . 
Glucose 6-phosphate dehydrogenase from trypanosomes: selectivity for steroids and chemical validation in bloodstream Trypanosoma brucei. Molecules
2021;26:358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7826790</ArticleId>
            <ArticleId IdType="pubmed">33445584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco J, Scarone L, Comini MA, Drugs and drug resistance in African and American Trypanosomiasis. In: Botta M, ed. Annual reports in medicinal chemistry: neglected diseases: extensive space for modern drug discovery. New York (NY): Academic Press, Elsevier Inc.; 2018:97–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Talevi A, Carrillo C, Comini M.. 
The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies. Curr Med Chem
2019;26:6614–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30259812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saccoliti F, Di Santo R, Costi R.. 
Recent advancement in the search of innovative antiprotozoal agents targeting trypanothione metabolism. ChemMedChem
2020;15:2420–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32805075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fyfe PK, Oza SL, Fairlamb AH, Hunter WN.. 
Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities. J Biol Chem
2008;283:17672–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2427367</ArticleId>
            <ArticleId IdType="pubmed">18420578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koch O, Cappel D, Nocker M, et al. . 
Molecular dynamics reveal binding mode of glutathionylspermidine by trypanothione synthetase. PLoS One
2013;8:e56788.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3581523</ArticleId>
            <ArticleId IdType="pubmed">23451087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leroux AE, Haanstra JR, Bakker BM, Krauth-Siegel RL.. 
Dissecting the catalytic mechanism of Trypanosoma brucei trypanothione synthetase by kinetic analysis and computational modeling. J Biol Chem
2013;288:23751–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3745322</ArticleId>
            <ArticleId IdType="pubmed">23814051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duty S, Jenner P.. 
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol
2011;164:1357–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3229766</ArticleId>
            <ArticleId IdType="pubmed">21486284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simeonov A, Kulkarni A, Dorjsuren D, et al. . 
Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One
2009;4:e57403rd.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2685009</ArticleId>
            <ArticleId IdType="pubmed">19484131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandramouly G, McDevitt S, Sullivan K, et al. . 
Small-molecule disruption of RAD52 rings as a mechanism for precision medicine in BRCA-deficient cancers. Chem Biol
2015;22:1491–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4701204</ArticleId>
            <ArticleId IdType="pubmed">26548611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devkota AK, Tavares CD, Warthaka M, et al. . 
Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact. Biochemistry
2012;51:2100–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3673019</ArticleId>
            <ArticleId IdType="pubmed">22352903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W, Fricke N, Conery AL, et al. . 
NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption. Future Med Chem
2016;8:257–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4976882</ArticleId>
            <ArticleId IdType="pubmed">26910612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlachojannis C, Magora F, Chrubasik S.. 
Rise and fall of oral health products with Canadian bloodroot extract. Phytother Res
2012;26:1423–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22318955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Debiton E, Madelmont JC, Legault J, Barthomeuf C.. 
Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion. Cancer Chemother Pharmacol
2003;51:474–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12700925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson KW, Coll RJ, Murphy AJ.. 
Inhibition of skeletal muscle sarcoplasmic reticulum CaATPase activity by calmidazolium. J Biol Chem
1984;259:11487–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6236226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gietzen K.
Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochem J
1983;216:611–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1152553</ArticleId>
            <ArticleId IdType="pubmed">6141789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Marchan Y, Sojo F, Rodriguez E, et al. . 
Trypanosoma cruzi calmodulin: cloning, expression and characterization. Exp Parasitol
2009;123:326–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19703447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terentis AC, Freewan M, Sempértegui Plaza TS, et al. . 
The selenazal drug Ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues. Biochemistry
2010;49:591–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20000778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu J, Vodnala SK, Gustavsson AL, et al. . 
Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei. J Biol Chem
2013;288:27456–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3779740</ArticleId>
            <ArticleId IdType="pubmed">23900839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joice AC, Harris MT, Kahney EW, et al. . 
Exploring the mode of action of Ebselen in Trypanosoma brucei hexokinase inhibition. Int J Parasitol Drugs Drug Resist
2013;3:154–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3862409</ArticleId>
            <ArticleId IdType="pubmed">24533305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharlow ER, Lyda TA, Dodson HC, et al. . 
A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis
2010;4:e659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2854128</ArticleId>
            <ArticleId IdType="pubmed">20405000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi T, Sano K, Takakura K, et al. . 
Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen study group. Stroke
1998;29:12–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9445321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masaki C, Sharpley AL, Cooper CM, et al. . 
Effects of the potential lithium-mimetic, Ebselen, on impulsivity and emotional processing. Psychopharmacology (Berl)
2016;233:2655–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4917572</ArticleId>
            <ArticleId IdType="pubmed">27256357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh N, Sharpley AL, Emir UE, et al. . 
Effect of the putative lithium mimetic Ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology
2016;41:1768–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4770517</ArticleId>
            <ArticleId IdType="pubmed">26593266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kil J, Lobarinas E, Spankovich C, et al. . 
Safety and efficacy of Ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet
2017;390:969–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28716314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Young J, Kima PE.. 
The Leishmania parasitophorous vacuole membrane at the parasite–host interface. Yale J Biol Med
2019;92:511–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6747952</ArticleId>
            <ArticleId IdType="pubmed">31543712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoine JC, Prina E, Jouanne C, Bongrand P.. 
Parasitophorous vacuoles of Leishmania amazonensis-infected macrophages maintain an acidic pH. Infect Immun
1990;58:779–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC258533</ArticleId>
            <ArticleId IdType="pubmed">1689700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alice JI, Bellera CL, Benítez D, et al. . 
Ensemble learning application to discover new trypanothione synthetase inhibitors. Mol Divers
2021;25:1361–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34264440</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
